electroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States
17 Julho 2018 - 9:00AM
electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic
medicine company, announced today a program with UpScript, a
digital healthcare platform, offering a direct-to-patient
telemedicine option for gammaCore™ non-invasive vagus nerve
stimulation (nVNS) therapy for patients with migraine and episodic
cluster headache in adults. gammaCore is the first FDA-cleared,
nVNS therapy that can be self-administered by patients as needed
for the acute treatment of pain associated with migraine and
episodic cluster headache. UpScript offers a convenient way for
prospective patients to consult with a licensed healthcare provider
via telephone or video to find out if they are candidates for
gammaCore.
“As a bioelectronic medicine company, we pride ourselves on
being on the cutting edge of health innovation,” said Dan Duhart,
Chief Commercial Officer, electroCore. “Through this program, we
will enable patients to access a healthcare provider no matter
where they are, and thereby expand access to people who may be
suffering from migraine or episodic cluster headache with a
convenient therapy like gammaCore.”
To use UpScript, patients follow three simple steps. First,
prospective patients create an account at
https://gammacore.com/get-started/, answer a few questions about
their medical history and input payment information. Then, users
schedule a telemedicine consultation to discuss their treatment
options, including gammaCore, via phone or video with one of
UpScript’s U.S. licensed healthcare providers. The consultation
will only take a few minutes and the healthcare provider will
determine if gammaCore should be prescribed. If the healthcare
provider prescribes gammaCore, gammaCore is shipped directly to the
patient. “When patients need care, they deserve to get it – easily,
quickly and discreetly. The UpScript program offers patients a
convenient option to access a healthcare provider and obtain the
appropriate treatment,” said Peter Ax, Chief Executive Officer,
UpScript. “We are excited to expand the UpScript portfolio to
include gammaCore, an innovative and easy-to-use technology that
will help patients treat the pain associated with migraine and
episodic cluster headache.” To learn more about gammaCore or to
schedule a consultation with UpScript, please visit:
https://gammacore.com/get-started/. About
gammaCore™gammaCore™ (nVNS) is the first non-invasive,
hand-held medical therapy applied at the neck that acutely treats
the pain associated with migraine and episodic cluster headache in
adult patients through the utilization of a mild electrical
stimulation to the vagus nerve that passes through the skin. When
placed on a patient’s neck over the vagus nerve, gammaCore
stimulates the nerve’s afferent fibers, which may lead to a
reduction of pain in patients.
gammaCore is released/cleared in the U.S. for the acute
treatment of pain associated with episodic cluster headache and
migraine headache in adult patients. gammaCore is currently
available outside of the U.S., including in the European Economic
Area, where it is CE-Marked.
IMPORTANT SAFETY INFORMATION REGARDING
GAMMACORE
- The safety and effectiveness of the gammaCore (nVNS) have not
been established in the acute treatment of chronic cluster
headache.
- gammaCore has not been shown to be effective for the
prophylactic treatment of chronic or episodic cluster headache or
migraine headache.
- The long-term effects of the chronic use of gammaCore have not
been evaluated.
- Safety and efficacy of gammaCore have not been
evaluated in the following patients, and therefore is NOT indicated
for:
- Patients with an active implantable medical device, such as a
pacemaker, hearing aid implant, or any implanted electronic
device
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis) Patients who have had surgery to cut the
vagus nerve in the neck (cervical vagotomy)
- Pediatric patients
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
- Patients should not use gammaCore if
they:
- Have a metallic device such as a stent, bone plate, or bone
screw implanted at or near their neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Note: This list is not all inclusive. Please refer to the
gammaCore Instructions for Use for all important warnings and
precautions before using or prescribing this product.
gammaCore is available by prescription only. U.S. Federal Law
restricts this device to sale by or on the order of a licensed
healthcare provider.
About electroCore, Inc.electroCore, Inc. is a
commercial-stage bioelectronic medicine company dedicated to
improving patient outcomes through its platform non-invasive vagus
nerve stimulation therapy. The company’s initial targets are the
acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com. About
UpScriptUpScript provides convenient customer experience
to obtain access to a healthcare provider and, if recommended, a
prescription for gammaCore™ non-invasive vagus nerve stimulation
(nVNS) therapy for migraine or episodic cluster headache, utilizing
telephone and video consultations. For more information, please
visit www.upscripthealth.com.
Media Contacts Alexandra CanaleGCI
Health617-921-9353Alexandra.canale@gcihealth.com
Peter Ax, CEOUpScript480-707-4534pax@upscripthealth.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024